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Abstract
Daily interruption of sedative therapy and limitation of deep sedation have been shown in several randomized trials
to reduce the duration of mechanical ventilation and hospital length of stay, and to improve the outcome of
critically ill patients. However, patients with severe acute brain injury (ABI; including subjects with coma after
traumatic brain injury, ischaemic/haemorrhagic stroke, cardiac arrest, status epilepticus) were excluded from these
studies. Therefore, whether the new paradigm of minimal sedation can be translated to the neuro-ICU (NICU) is
unclear. In patients with ABI, sedation has ‘general’ indications (control of anxiety, pain, discomfort, agitation,
facilitation of mechanical ventilation) and ‘neuro-specific’ indications (reduction of cerebral metabolic demand,
improved brain tolerance to ischaemia). Sedation also is an essential therapeutic component of intracranial pressure
therapy, targeted temperature management and seizure control. Given the lack of large trials which have evaluated
clinically relevant endpoints, sedative selection depends on the effect of each agent on cerebral and systemic
haemodynamics. Titration and withdrawal of sedation in the NICU setting has to be balanced between the risk that
interrupting sedation might exacerbate brain injury (e.g. intracranial pressure elevation) and the potential benefits of
enhanced neurological function and reduced complications. In this review, we provide a concise summary of
cerebral physiologic effects of sedatives and analgesics, the advantages/disadvantages of each agent, the
comparative effects of standard sedatives (propofol and midazolam) and the emerging role of alternative drugs
(ketamine). We suggest a pragmatic approach for the use of sedation-analgesia in the NICU, focusing on some
practical aspects, including optimal titration and management of sedation withdrawal according to ABI severity.
Background
It is now well established, based on randomized trials
conducted in the general ICU adult and paediatric popula-
tions, that minimizing or avoiding sedation provides a bet-
ter outcome, including shorter duration of mechanical
ventilation and length of hospital stay [1]. Less sedation
also facilitates early mobilization, reduces the need for
additional examinations such as cerebral computed
tomography scan or electroencephalography (EEG) to
assess brain function, and might reduce delirium and
healthcare costs [2].
Patients with severe acute brain injury (ABI; including
severe traumatic brain injury, poor-grade subarachnoid
haemorrhage, severe ischaemic/haemorrhagic stroke,
comatose cardiac arrest, status epilepticus) have tradition-
ally been kept deeply sedated, at least in the early phase
following ICU admission. Sedation has specific roles
following ABI. First, sedation/analgesia is used for control
of pain, anxiety, agitation and patient–ventilator synchrony.
Second, sedation/analgesia has additional ‘neuro-specific’
indications in the acute phase that might significantly
influence its use in this setting [3]. Whether a strategy of
avoiding sedation is applicable to neurointensive care is
unknown: this must be balanced between the potential
benefit that daily interruption of sedation might have on
enhancing awakening and monitoring of neurological
function and the risk that stopping sedatives (hypnotics)
and analgesics (opioids) might exacerbate intracranial
hypertension in patients with reduced brain compliance.
In addition, ABI patients were generally excluded from
randomized trials on sedation, and therefore the level of
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evidence to guide sedative choice or algorithms for sed-
ation–analgesia management is generally low [4, 5].
In this review, we provide a concise summary of the
main cerebral physiologic effects of sedatives and analge-
sics, the advantages/disadvantages of each agent, the com-
parative effects of standard sedatives (mainly propofol and
midazolam) in patients with ABI, and the emerging role of
alternative sedatives, particularly ketamine. ICU delirium
is not covered here, because no delirium assessment tools
have been validated in the ABI population. We suggest a
practical approach for the use of sedation and analgesia in
the neuro-ICU (NICU), with specific attention on how to
best initiate, titrate and stop sedation, according to ABI
severity.
Rationale for the use of sedation and analgesia
after ABI
In patients with ABI, sedation exerts specific cerebral
protective effects which can be summarized as follows.
Effects on the cerebral metabolic rate of oxygen
consumption
The cerebral metabolic rate for oxygen (CMRO2) and
cerebral blood flow (CBF) are finely coupled. After ABI,
interventions are targeted to both increase cerebral oxygen
delivery and/or attenuate cerebral metabolic demand,
aiming to provide adequate oxygen availability and
energy balance at the neuronal level. In this setting,
sedative agents act by reducing CMRO2, improving
cerebral tolerance to ischaemia and limiting supply/
demand mismatch in conditions of impaired autoregula-
tion [6, 7]. The metabolic suppression of CMRO2 with sed-
atives is generally dose dependent, until the EEG becomes
isoelectric. Beyond this level, no further suppression of
cerebral oxygen consumption can occur, while minimal
consumption persists for cellular homeostasis [8, 9].
Effects on CBF
All intravenous sedative agents cause a dose-dependent
decrease in CBF [6–9], although CBF reductions with
benzodiazepines tend to be more variable than those
with propofol, probably because benzodiazepines do not
easily produce burst suppression or an isoelectric EEG.
Infusions of remifentanil may produce reduction in CBF
similar to that seen with intravenous anaesthetics [10].
CBF reduction is an adaptive phenomenon to dimin-
ished brain metabolism. While sedatives exert a coupled
reduction of CBF/CMRO2, they often have systemic
haemodynamic side effects, by decreasing mean arterial
blood pressure (MAP) and also by inducing myocardial
depression and peripheral vasodilatation. In patients
with impaired autoregulation, lowering MAP might pro-
duce a critical decrease in cerebral perfusion pressure
(CPP) and oxygen delivery to the brain, thereby leading
to secondary brain tissue ischaemia/hypoxia [6, 7]. Even
when CBF autoregulation is preserved, MAP reduction
can lead to an increase in intracranial pressure (ICP) as
a result of compensatory vasodilation [11]. High bolus
doses of opioids trigger cerebral vasodilatation in response
to reductions in MAP and have been associated with in-
creases in ICP and decrease of CPP [12]. These negative
effects can be largely prevented if MAP is maintained. Sys-
temic haemodynamic effects are usually dose dependent;
therefore, to minimize the risk of hypotension and re-
duced CPP, it is important to carefully assess preload and
ensure normovolemia in all patients, particularly in those
with pre-existing heart disease.
Control of ICP
Sedatives and analgesics may reduce ICP by different
mechanisms [3]. First, they induce a reduction in
CMRO2 and, consequently, in CBF, leading to a parallel
decrease in cerebral blood volume. This decrease in
cerebral blood volume will produce a reduction of intra-
cranial volume and, therefore, ICP. Second, sedation and
analgesia reduce pain and agitation, which may cause
arterial hypertension and associated ICP surge. Third,
analgesia improves tolerance of the endotracheal tube
and, by reducing agitation and coughing, avoids increases
in intrathoracic pressure, which can reduce jugular venous
outflow and raise ICP. For all of these reasons, sedation
and analgesia protect the brain against intracranial
hypertension and brain hypoperfusion.
Seizure suppression
Seizures produce an increase in cerebral metabolism and
possibly a mismatch between oxygen delivery and metab-
olism. Together with anti-epileptic drugs, sedation re-
duces the occurrence of seizures in the NICU [13].
Standard or high-dose propofol infusion (2 mg/kg induc-
tion bolus followed by 150–200 μg/kg/min infusion) can
reliably be used as an anticonvulsant and for the control
of status epilepticus. A recent statement by the European
Federation of Neurological Societies included propofol as
a treatment of generalized convulsive status epilepticus
[14]. Thus, both benzodiazepines and propofol can be
selected in ABI patients to reduce the risk of secondary
seizures. These agents, together with barbiturates, are γ-
aminobutyric acid receptor agonists and are used for the
management of refractory status epilepticus. Ketamine is
an N-methyl-D-aspartate receptor antagonist and consti-
tutes an alternative or adjunct agent to standard γ-
aminobutyric acid receptor antagonists in this setting [15].
Control of spreading depression
Cortical spreading depolarization (also termed spreading
depression) is a type of pathological brain electrical
activity that, by worsening energy balance, can cause
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lesion expansion in traumatic brain injury, intracranial
haemorrhage and other forms of ABI [16]. Spreading
depolarization results in pervasive mass depolarization of
neurons and glia; it is initiated near the lesion core, and
propagates slowly (2–6 mm/min) through adjacent cortex,
with catastrophic disruption of electrochemical gradients
and loss of local neuronal function. Restoration of electro-
chemical equilibrium is an energy-demanding process,
which can further worsen oxygen and substrate supply-
demand imbalances in penumbral tissue and can promote
lesion growth when oxygen and substrate supply are
limited. Since the frequency and intensity of spreading
depolarizations have been associated with outcome in
human brain injury, it is important to recognize that they
can be modulated depending on the type of sedative agent
used. In one recent study—when compared with opioids,
midazolam and propofol—sedation with ketamine was
associated with the lowest incidence of spreading depolar-
izations [17]. Since spreading depolarization is a potentially
modifiable secondary injury mechanism, these findings
make a strong case for a trial of ketamine containing
sedative regimes in patients with ABI.
Indications for sedation in ABI patients
General indications
Continuous infusion of sedative and opioid agents is gen-
erally considered to protect the injured brain in the acute
phase (first 24 h up to 48 h), especially in comatose NICU
patients with severe injury and abnormal head computed
tomography, to prevent pain, anxiety and agitation and to
enable mechanical ventilation.
Specific indications
Sedation/analgesia is part of management in other par-
ticular conditions, which include targeted temperature
management (TTM), elevated ICP and refractory status
epilepticus:
 Targeted temperature management. Indications for
TTM include post-cardiac arrest coma, neurogenic
fever and ICP control. Sedation and analgesia is
recommended during TTM to avoid shivering, to
improve patient-ventilator synchrony and potentially
to blunt the endogenous stress response [18]. All
randomized trials investigating the use of TTM used
a sedation protocol during the cooling period. It
remains unknown whether sedation per se provided
additional neuroprotective effects. However, it is
important to recognize that sedation may also increase
the duration of mechanical ventilation and, by delaying
neurological responses, might reduce the accuracy of
clinical examination to assess prognosis [19].
 Elevated ICP. Sedation/analgesia is a first-line therapy
in the management of elevated ICP, together with
other specific measures, including controlled
hyperventilation, CPP-guided head-of-bed elevation
and osmotic agents [20]. In most cases, elevated ICP
develops after 48 h from the time of the brain insult
(e.g. traumatic brain injury), but in other conditions it
may develop at an earlier phase (e.g. severe intracranial
haemorrhage). Elevated ICP may persist for several
days, and therefore aggressive and prolonged sedation/
analgesia is generally required.
 Status epilepticus. Another condition that requires
timely and deep sedation is refractory status
epilepticus, which occurs in several primary and
secondary forms of brain injury when both
emergency therapy (e.g. benzodiazepines) and
first-line therapy (e.g. anti-epileptic drugs) fail to
control seizures. In this condition, the use of an
anaesthetic agent is recommended, which will be
followed by a slow reduction of drug regimens after
at least 24 h of effectiveness and the maintenance of
anticonvulsants to keep seizures under control [21].
 Paroxysmal sympathetic activity. Paroxysmal
sympathetic activity represents a particular case
in which sedative agents may be considered to
attenuate excessive autonomic activation and
motor hyperactivity [22].
In all other conditions, sedation has no specific role
and should be limited as in the general ICU. This will
allow repeated daily clinical examination, which remains
the most accurate way to detect neurological worsening
in this scenario [23]. Light sedation and pain control
might be considered in case of agitation when all other
treatable causes have been excluded, before invasive ma-
noeuvres (e.g. such as endotracheal aspiration) and in
cases of severe patient-ventilator asynchrony.
How to select sedatives and analgesics in the NICU
Standard sedatives
The choice of the adequate sedative in NICU patients
should consider all potential advantages and disadvan-
tages (Table 1) as well as the clinical scenario (Table 2).
Propofol is currently used in many ICUs for the man-
agement of ABI patients and is recommended for the
control of ICP [24]. Propofol increases the depth of sed-
ation in a dose-dependent manner: at doses <4 mg/kg/h,
CBF/CMRO2 coupling, cerebrovascular reactivity and
brain oxygenation are preserved [25]; while at higher
doses (>5 mg/kg/h), propofol can induce EEG burst sup-
pression that can be effective to treat status epilepticus
[8]. Weaning from mechanical ventilation occurs earlier
than with midazolam [26].
Midazolam, despite its relatively short (1-h) half-life, is
more susceptible to tissue accumulation because of
high lipid solubility, and thus may prolong the time
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Table 1 Mechanism of action, cerebral physiologic effects and main advantages/disadvantages of sedatives/analgesics in patients with acute brain injury
Mechanism of action CNS effects Advantages Disadvantages
Propofol GABA-R agonist ↓ ICP Rapid onset and short duration of action No amnesia, especially at low doses
↓ CMRO2, ↓ CBF, preserved CO2
reactivity and cerebral autoregulation
Clearance independent of renal or
hepatic function
No analgesic effect
↓ Cerebral electrical activity, can be
used to induce EEG burst suppression
(at high dose)
No significant drug interactions Tolerance and tachyphylaxis
↓ MAP, ↓ CPP (particularly in
hypovolemic patients)
↑ Triglycerides, ↑ caloric intake
Propofol infusion syndrome
(↓ HR, ↓ pH, ↑ lactate, ↑ CPK,
myocardial failure)
Midazolam GABA-R agonist ↓ CMRO2, ↓ CBF Amnesia Tolerance and tachyphylaxis
Slight ↓ ICP Rapid onset of effect in acutely agitated
patient
Hepatic metabolism to active
metabolite
Preserved CO2 reactivity and cerebral
autoregulation
Less haemodynamic instability than
propofol (may prevent CPP reductions)
May accumulate in renal dysfunction
Anti-epileptic effect May prolong the duration of MV
May increase ICU delirium
Barbiturates GABA-R agonist ↓↓ CBF that is proportional to the
↓↓ CMRO2 (up to 60 %) during
burst suppression
By ↓↓ CBF and CBV, barbiturates
have a strong effect on ↓↓ ICP
Hypotension, ↓↓ MAP/CPP
↓↓ ICP Indications for barbiturates are limited to
the treatment of refractory ICP and refractory
status epilepticus, titrated to the lowest
effective dose; EEG may help with the titration
of barbiturate therapy
Immune suppression, increased risk
of infections (pneumonia)
Adrenal dysfunction
Morphine μ-receptor agonist ↑ ICP and ↓ MAP/CPP transiently
following bolus
Low cost Low predictability to control ICP
Histamine release
Accumulation with hepatic/renal
impairment
Fentanyl, sufentanil μ-receptor agonists ↑ ICP and ↓ MAP/CPP transiently
following bolus
More potent opioid than morphine
(sufentanil is 1000× more potent
than morphine)
Accumulation with hepatic
impairment
Control ICP during endotracheal
suctioning
May prolong the duration of MV
Remifentanil μ-receptor agonist No changes in ICP or CBF during
drug infusion
500× more potent than morphine Hyperalgesia at the cessation of
drug infusion
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Table 1 Mechanism of action, cerebral physiologic effects and main advantages/disadvantages of sedatives/analgesics in patients with acute brain injury (Continued)
Rapid onset and short duration of action
to permit neurological assessment
Limited effect to control ICP during
painful procedures
Clearance independent of renal or
hepatic function
Tachyphylaxis
Higher cost than other opiates
Dexmedetomidine α2-agonist ICP ↓ or unchanged Sedative, analgesic and anxiolytic Very limited clinical experience in
patients with ABI
CPP ↑ or unchanged Short acting, no accumulation, patient
may be frequently assessed neurologically
In non-neurointensive care
population:
SjvO2 unchanged Minimal respiratory depression ● hypotension, bradycardia
PbtO2 unchanged May reduce incidence/severity
of delirium
● arrhythmias including atrial fibrillation
● hyperglycaemia
May require high doses; deep
sedation may not be possible
High cost
Ketamine NMDA-R antagonist ICP ↓ or unchanged Short acting, fast onset Hallucinations/emergence phenomena
CPP ↑ or unchanged Induces sedation, analgesia and anaesthesia
No change in SjvO2 or cerebral
blood flow velocities
Does not depress respiration
Haemodynamic stability, preserves MAP
May be used as an adjunct for
refractory seizures
No withdrawal symptoms
Inhaled anaesthetics Not fully established: may act at
several sites (reduction in junctional
conductance; activation of Ca2+-dependent
ATP-ase; binding to the GABA-R, the large
conductance Ca2+-activated K+ channel, and
the glutamate receptor)
↓ Cerebral electrical activity,
↓ CMRO2
↑ CBF in patients with cerebral
ischaemia (0.8 % isoflurane)
↑ ICP due to ↑ CBV
Dose-dependent effects on CBF:
↓ CBF at low concentrations,
↑ CBF at high concentrations
Rapid elimination Myocardial depression
Malignant hyperthermia
Not widely available, requires
specific systems and expertise
Data very preliminary
ABI acute brain injury, ATP adenosine triphosphate, CBF cerebral blood flow, CBV cerebral blood volume, CMRO2 cerebral metabolic rate of oxygen consumption, CNS central nervous system, CO2 carbon dioxide, CPK
creatine phosphokinase, CPP cerebral perfusion pressure, EEG electroencephalography, GABA-R γ-aminobutyric acid receptor, HR heart rate, ICP intracranial pressure, MAP mean arterial pressure, MV mechanical
ventilation, NMDA-R N-methyl-D-aspartate receptor, PbtO2 brain tissue oxygen pressure, SjvO2 jugular venous bulb saturation
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to awakening and confound clinical assessment [27]. Delay
in awakening following prolonged midazolam infusion has
a large interindividual variability [28, 29]. Tachyphylaxis
can lead to increasingly higher doses and difficulty con-
trolling ICP; and withdrawal symptoms may occur at drug
discontinuation. Benzodiazepines have been linked to ICU
delirium [30], although data in ABI patients are limited.
Midazolam may be preferred over propofol in patients
with haemodynamic instability. Other benzodiazepines,
such as lorazepam, because of their longer half-life, are
less suitable for continuous sedation in ABI patients.
Propofol and midazolam can be used as first-line seda-
tive agents in ABI patients, and their utilization appears
variable among clinicians and countries depending on
individual practices and/or cost-related issues [31]. A
systematic review from 13 randomized controlled trials
including a total of 380 patients with traumatic brain in-
jury found propofol and midazolam to be equally effica-
cious in improving ICP and CPP [12]. When selecting
between these two agents, additional important aspects
need to be considered, particularly with respect to efficacy
in controlling ICP, effects on cerebral and systemic
haemodynamics, and the potential for prolonged duration
of mechanical ventilation and ICU stay:
 Available comparative studies show propofol and
midazolam appear equally effective as routine
sedative agents in controlling ICP in unselected ABI
patients at risk of intracranial hypertension [12].
 In patients with severe or refractory ICP, despite
lack of good quality comparative data, there is a
common clinical assumption that propofol may be
more effective in lowering high ICP because of its
more pronounced effect on brain metabolism.
 Both agents may cause hypotension and a reduction
in CPP, although this is more frequent with propofol
than with midazolam [12].
 ICP control with midazolam may require
increasingly high doses, with ensuing drug
bioaccumulation and prolonged duration of coma,
mechanical ventilation and ICU length of stay [12].
 Because of accumulation, prolongation in half-life
and the risk of propofol infusion syndrome (PRIS)
particularly at high doses (i.e. >4 mg/kg/h), propofol
alone may be insufficient to control ICP [32].
 Propofol is more expensive than midazolam.
Alternative sedatives
Ketamine is an N-methyl-D-aspartate receptor antagon-
ist, a short-acting agent with a rapid onset of action that
does not alter systemic haemodynamics or respiratory
drive, so it can be used in non-intubated patients.
Ketamine (1–5 mg/kg/h) can be used as an adjunct to
standard sedatives to reinforce their effects and limit
excessive drug requirement. At lower doses, it can also
be used as an alternative or adjunct to opioid analgesia.
Ketamine is less prone to hypotension than the other
sedatives.
The use of ketamine has been debated because of the
concern raised by early studies that it was associated
with ICP increase [33]. These early findings were not
confirmed, however, by more recent studies in adults
and children with ABI. In studies examining the cerebral
haemodynamic effects of ketamine after ABI, ICP was
Table 2 Suggested options for sedation–analgesia after acute brain injury, according to clinical scenario and organ function
Indication First-line sedative First-line analgesic Alternatives
‘Standard’ sedation, no ICP elevation Propofol Fentanyl Sufentanil
Midazolam Morphine Remifentanil
Elevated ICP Propofol Fentanyl Sufentanil
Midazolam Morphine Remifentanil
Targeted temperature management Propofol Fentanyl Sufentanil
Midazolam Morphine Remifentanil
Status epilepticus Propofol Fentanyl Sufentanil
Midazolam Morphine Remifentanil
Liver dysfunction Propofol Fentanyl –
Sufentanil
Remifentanil
Renal dysfunction Propofol Remifentanil –
Haemodynamic instability Midazolam Fentanyl Ketamine
Agitation, delirium α2-agonists Fentanyl Antipsychotics
Morphine
ICP intracranial pressure
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reduced and CPP remained stable or increased, without
significant changes in cerebral haemodynamics [34].
During clinical interventions such as endotracheal suc-
tioning, ICP remains stable or increases modestly [35].
Finally, a recent systematic review concluded that keta-
mine was not associated with an increased risk of ICP
elevation, as reported previously [36]. In light of these
findings, ketamine should be considered after ABI.
Dexmedetomidine is a selective α2-adrenergic agonist
with rapid distribution and elimination that does not
accumulate and therefore could be ideally suitable for
reliable neurological examination in ABI patients.
Dexmedetomidine and propofol proved equally effective
at maintaining sedation, with no significant difference in
systemic or cerebral parameters [37, 38]; however, these
data are from small single-centre studies. Given the very
limited data and the considerably higher cost than trad-
itional sedatives (including propofol), dexmedetomidine
cannot be recommended at the present time for the
sedation of ABI patients. Despite limited clinical data,
clonidine—an α2-adrenergic agonist with a longer
half-life and lower cost than dexmedetomidine—is fre-
quently used in practice as an adjunctive sedative in the
de-escalation phase of NICU sedation.
Inhaled sedatives
Volatile agents such as sevoflurane and isoflurane are
emerging as an alternative for ICU sedation. In patients
with acute cerebrovascular disease (ischaemic stroke
and subarachnoid haemorrhage), sevoflurane was effective
as a sedative agent but was associated with a significant
increase in ICP [39, 40]. In patients with subarachnoid
haemorrhage without intracranial hypertension, however,
0.8 % isoflurane significantly improved regional CBF with
only a modest effect on ICP when compared with
propofol [41]. While this effect may be beneficial in
the setting of delayed cerebral ischaemia, the available
data suggest a microvascular site of action [42] and do not
show whether isoflurane (or other volatile agents) can
reverse large vessel vasospasm in subarachnoid haemor-
rhage. An important limitation for inhaled sedatives at this
stage is that data are very preliminary and delivery re-
quires specific systems and expertise.
Finally, barbiturates (thiopental or pentobarbital) are
not discussed here since they should not be used as seda-
tive agents in the NICU because of their numerous side
effects (mainly cardiocirculatory and immune depression).
However, barbiturates can be considered in selected ABI
patients with refractory intracranial hypertension [24] or
refractory status epilepticus [43].
Analgesics
Schematically, two clinical situations may impact on the
choice of opioids. If a deep state of sedation/analgesia is
required to control ICP and to blunt reactions to noxious
stimuli, opioid agents such as fentanyl or sufentanil are
preferable in association with sedatives (Table 1). On the
other hand, if the initial brain insult needs to be reassessed
during a neurological wake-up test without compromising
ICP, short-acting agents such as remifentanil may be more
advantageous than a combination of a sedative with fen-
tanyl or morphine [44].
Because it is now recommended in the general ICU
population to minimize opiate administration, we sug-
gest the concomitant use of non-opioid analgesics such
as paracetamol and gabapentin [1]. Moreover, it is essen-
tial to distinguish pain from other conditions such as
anxiety or agitation/delirium, where anti-psychotic
agents such as haloperidol or—to avoid extra-pyramidal
side effects—quetiapine and risperidone may be useful
adjuncts.
A practical approach for the use of sedation and
analgesia in the NICU
A practical algorithm for the management of sedation
in the NICU is proposed in Fig. 1. The approach to
sedation should first consider the severity of ABI and
the cerebral physiological state, mainly ICP. Attention
should be given to adequately control pain, control
agitation and promote ventilator synchrony. In patients
with intracranial hypertension, ICP and multimodal moni-
toring is an important asset and therapeutic targets for
sedation and analgesia should be titrated to control ICP
and (when available) brain tissue oxygen pressure (PbtO2).
The implementation of local protocols for sedation-
analgesia which incorporate a clinical sedation target may
limit excessive sedation [45].
Monitoring of sedation and analgesia in the NICU
Conventional validated sedation scoring tools for critical
care, such as the Richmond Agitation Sedation Scale
and the Sedation-Agitation Scale, may be reasonable to
use in ABI patients [46]. However, in deeply sedated pa-
tients or in those treated with neuromuscular blocking
agents, the role of EEG to monitor sedation has been a
topic of clinical investigation. Simplified EEG tools pro-
viding quantitative bispectral index (BIS) monitoring
showed that BIS values significantly correlated with
Richmond Agitation Sedation Scale and Sedation-
Agitation Scale scores in ABI patients [47]. In another
study, the BIS reliably assessed sedation levels during
continuous propofol infusion in traumatic brain injury
patients [48]. Utilization of BIS in the NICU was limited
by the reliability of these techniques (muscle artefacts,
shivering) in the particular environment of the ICU.
Also, the BIS was initially developed for monitoring the
depth of general anaesthesia in patients without brain
pathology. ABI may influence the BIS algorithm because
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of EEG changes related to the pathology itself rather
than to the sedative state. Whether new EEG techniques
will allow better sedation monitoring in the NICU needs
further investigation.
Assessment of the adequacy of analgesia presents special
challenges. The Numeric Rating Scale is the preferred ap-
proach in alert patients, with either the Behavioral Pain
Scale or the Critical Care Pain Observation Tool in subjects
who are not able to respond. However, uncertainties remain
about the performance of these scales in ABI patients [49].
The Nociception Coma Scale has recently emerged as
a valid tool to assess pain in patients with disorders
of consciousness [50]. The determination of the adequacy
of analgesia for these patients still relies upon the observa-
tion of indirect signs of pain; for example, tachycardia,
systemic hypertension and elevation in ICP during painful
interventions.
Pharmacology and side effects
Renal dysfunction
In patients with renal dysfunction, dose reduction should
be considered for most sedatives and analgesics, because
of their hydrophilic properties and their metabolism,
which is largely affected by renal clearance [51]. Propofol
is minimally affected by renal failure [52].
Liver dysfunction
Propofol concentrations will increase in case of reduced
liver perfusion, while altered hepatic function with pre-
served flow will minimally influence drug levels [53].
However, as propofol is highly protein bound (97–99 %)
and its vehicle is a lipid-containing emulsion, changes in
albumin levels and disorders of fat metabolism associ-
ated with liver dysfunction may significantly increase
drug concentrations and the risk of side effects [54].
Benzodiazepines such as diazepam and midazolam, be-
cause their metabolism is dependent on CYP450 activity,
are associated with slower clearance and higher concentra-
tions in case of hepatic dysfunction [55].
Among opioids, intravenous morphine may result in
higher than expected concentrations in cases of renal
or liver dysfunction, while other drugs such as fentanyl
or sufentanil are less affected [56, 57]. Remifentanil is
the opioid drug that is least influenced by hepatic and
renal dysfunction because of its large extra-hepatic me-
tabolism (i.e. rapid hydrolysis by non-specific tissue and
plasma esterases) [58].
Impaired cardiovascular function
Midazolam and, even more so, propofol can induce
hypotension and haemodynamic compromise, particularly
Fig. 1 Suggested approach to the management of sedation–analgesia in neurointensive care patients. Note: clinical and neuro-radiological
follow-up and indications to intracranial monitoring must be evaluated in all patients. High intracranial pressure (ICP) defined as >20 mmHg
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in the hypovolemic patient. The use of ketamine could re-
duce the need for benzodiazepines or propofol and reduce
the risk of hypotension [59]. Some drugs, such as α2-ago-
nists, should be avoided because of the potential induction
of hypotension or bradycardia, which could further
compromise the haemodynamic instability [60].
Agitation and delirium
Delirium and agitation can largely complicate the clin-
ical course of ABI patients [61]. No delirium scales have
been validated in an ABI population and there is no evi-
dence that antipsychotics improve any clinical outcomes.
Haloperidol can be used to treat delirium symptoms in
critically ill patients but may increase the brain suscepti-
bility to develop seizures [62]. Alternatively, quetiapine or
risperidone may be used. Benzodiazepines can be effective
to reduce agitation, but they could obscure the neuro-
logical examination and potentially burden the severity of
delirium [30]. Thus, α2-agonists could be a valuable thera-
peutic option [63].
Propofol infusion syndrome
PRIS is a rare but potentially fatal complication character-
ized by severe metabolic acidosis and cardiocirculatory
shock [64]. Risk factors for PRIS include high propofol
dosage (>4 mg/kg/h), prolonged utilization (>48 h), neuro-
logic or neurosurgical diseases, young age, catecholamine
or glucocorticoid administration, inadequate dietary car-
bohydrates and subclinical mitochondrial disease [65]. In
addition, therapeutic hypothermia may precipitate PRIS in
patients on ‘safe’ doses of propofol by reducing its hepatic
metabolism and increasing plasma levels [66].
Withdrawal of sedation in NICU patients
Based on trials in the general ICU population, it is clear
that patients have improved outcomes with sedation
minimization strategies such as daily sedation interrup-
tion (SI) [67]. However, sedation minimization is not
easily applicable to NICU patients, particularly in the
acute phase [68]. Furthermore, sedation has ‘neuro-spe-
cific’ indications and ABI patients generally were ex-
cluded from studies evaluating the impact of SI [4, 5], so
data from these trials cannot be extrapolated to the
NICU population. Indeed, in a survey conducted in 16
Scandinavian centres, half of them never performed
neurological wake-up tests in sedated ABI patients [31].
Withdrawal of sedation and SI by daily wake-up tests
may appear beneficial to NICU patients by allowing clin-
ical neuro-monitoring and timely detection of warning
neurological signs [69]. Daily SI trials have the potential
to reduce mechanical ventilation duration and the need
for tracheostomy [70]. These potential benefits, however,
must be balanced against the risk of further cerebral
haemodynamic deterioration when sedation is stopped
abruptly [68]. SI may lead to significant ICP elevation
and CPP reductions, which were more relevant in the
first days after ABI than after 4–5 days [71]. Skoglund et
al. [69] showed that abrupt SI for neurological wake-up
tests increased circulating levels of stress hormones,
such as cortisol and endogenous catecholamines, was as-
sociated with clinical signs of adrenergic activation and
was associated with a slight but significant increase in
ICP. Given that adrenergic activation might exacerbate
secondary brain injury and that sympathetic blockade
improves neurological outcome in both experimental
and human settings [72], the use of SI may raise concern
in the setting of ABI. Furthermore, while SI may cause
an unwanted increase of ICP and decrease of PbtO2, the
strategy also actually detected new neurological signs
only in a very low number of wake-up tests [68].
A reasonable approach is to recommend avoidance of SI
in all patients at risk for (clinical and radiological signs of
brain oedema) or having ICP elevation, and in those under-
going TTM and treatment of refractory status epilepticus.
In these patients, sedation should never be stopped
abruptly but rather withdrawn progressively, titrating the
sedation dose to ICP (and, if available, PbtO2) targets. In all
other ABI patients, withdrawal should proceed as in the
general ICU and daily SI is not contraindicated.
Conclusions
Sedation and analgesia is frequently used in neurointen-
sive care both for ‘general’ (reduction of pain, anxiety,
discomfort, patient–ventilator asynchrony) and ‘neuro-
specific’ indications (ICP control, TTM, seizure manage-
ment). Sedation is not without risk and, as in the general
ICU, might prolong the length of stay and impact mor-
bidity and mortality. Management of sedation/analgesia
is based on consideration of the patient clinical scenario,
potential benefits and risks, and the side effects related
to each agent. Midazolam and propofol are most fre-
quently used and recommended as first-line sedatives. In
comparative studies, both agents are equally effective in
controlling ICP, but midazolam may prolong the dur-
ation of mechanical ventilation and ICU stay. Amongst
alternative agents, ketamine appears promising. Because
of limited data, dexmedetomidine cannot be recom-
mended at this time in the NICU.
A practical approach should be used in the NICU, in-
dividualized to the severity of ABI and intracranial
monitoring-derived therapeutic targets (ICP, CPP and
PbtO2), aiming to optimize analgesia and to minimize
sedative doses.
Note
This article is part of a series on Neurocritical care, edi-
ted by Fabio Taccone. Other articles in this series can be
found at http://ccforum.com/series/NCRC.
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